8-K filing — Generate Biomedicines, Inc. (GENB)
Filed: 2026-08-26 AccNo: 0001193125-26-365556 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate
Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 73.2 percent increase over losses of $(1.94) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 11:37 AM
- Checked
- Aug 6, 2026, 11:37 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Generate Biomedicines shares are trading lower after the company reported mixed Q2 financial results.
Read original at benzingaCathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday
Cathie Wood's Ark Invest expanded positions in three recently-IPO'd stocks on Monday: Space Exploration Technologies (SpaceX), Generate Biomedicines, and Bullish. SpaceX, trading 19% above its IPO price, joins the Nasdaq-100 on Tuesday which should drive passive buying. Generate Biomedicines, a clinical-stage biotech company with AI-driven drug discovery, is trading above its February IPO price. Bullish, a crypto exchange and media company, has plummeted 72% since going public due to crypto market weakness.
Read original at the-motley-fool